Objective,2,To observe the clinical effect of Biejia Ruangan Formula Granules combined with Entecavir in treating chronic hepatitis B liver fibrosis due to deficiency of qi and yin and obstruction of collaterals by blood stasis.,Methods,2,EEighty patients with chronic hepatitis B liver fibrosis of deficiency of qi and yin type and obstruction of collaterals by blood stasis type were randomly divided into a control group and an observation group， with 40 cases in each group. The control group was treated with orally taking Entecavir Dispersible Tablets， while the observation group was treated with Biejia Ruangan Formula Granules on the basis of the control group. Both groups were treated for 6 months. The indexes of liver function， liver hardness （LSM）， serum liver fibrosis， virology and safety were compared before and after treatment.,Results,2,After treatment， the levels of alanine aminotransferase （ALT）， aspartate aminotransferase （AST） and total bilirubin （TBIL） in the two groups were lower than those before treatment （P ,<, 0.05）， and there was no significant difference in ALT， AST and TBIL between the two groups（,P,>,0.05）. After treatment， the LSM of patients in both groups was lower than that before treatment（,P,<,0.05）， and the LSM of patients in the observation group was lower than that in the control group（,P,<,0.05）. After treatment， the serum hepatic fibrosis indexes of the two groups were lower than those before treatment（,P,<,0.05）， and the serum hepatic fibrosis indexes of the observation group were lower than those of the control group（,P,<,0.05）. After treatment， there was no significant difference in the negative conversion rate HBV⁃DNA and HBeAg between the two groups（,P,>,0.05）.,Conclusion,2,Biejia Ruangan Formula Granules combined with Entecavir can effectively reduce the degree of liver fibrosis in treating chronic hepatitis B patients with liver fibrosis of deficiency of qi and yin type and obstruction of collaterals by blood stasis type.